Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis

BMC Nephrology

Jeffrey A. Linder¹  Sushrut S. Waikar²  Adam Wright¹  Lipika Samal¹ 

[1] Harvard Medical School, Boston 02120, MA, USA;Renal Division, Brigham and Women’s Hospital, 75 Francis St., Boston 02120, MA, USA

关键词: Kidney diseases;    Ambulatory care;    Quality of healthcare;    Nephrology;    Primary care;   

Others  :  1228730
DOI  :  10.1186/s12882-015-0154-x

 received in 2015-05-06, accepted in 2015-09-28,  发布年份 2015

【 摘 要 】

Background

Primary care physicians (PCPs) typically manage early chronic kidney disease (CKD), but recent guidelines recommend nephrology co-management for some patients with stage 3 CKD and all patients with stage 4 CKD. We sought to compare quality of care for co-managed patients to solo managed patients.

Methods

We conducted a retrospective cross-sectional analysis. Patients included in the study were adults who visited a PCP during 2009 with laboratory evidence of CKD in the preceding two years, defined as two estimated glomerular filtration rates (eGFR) between 15–59 mL/min/1.73 m ²separated by 90 days. We assessed process measures (serum eGFR test, urine protein/albumin test, angiotensin converting enzyme inhibitor or angiotensin receptor blocker [ACE/ARB] prescription, and several tests monitoring for complications) and intermediate clinical outcomes (mean blood pressure and blood pressure control) and performed subgroup analyses by CKD stage.

Results

Of 3118 patients, 11 % were co-managed by a nephrologist. Co-management was associated with younger age (69 vs. 74 years), male gender (46 % vs. 34 %), minority race/ethnicity (black 32 % vs. 22 %; Hispanic 13 % vs. 8 %), hypertension (75 % vs. 66 %), diabetes (42 % vs. 26 %), and more PCP visits (5.0 vs. 3.9; p < 0.001 for all comparisons). After adjustment, co-management was associated with serum eGFR test (98 % vs. 94 %, p = <0.0001), urine protein/albumin test (82 % vs 36 %, p < 0.0001), and ACE/ARB prescription (77 % vs. 69 %, p = 0.03). Co-management was associated with monitoring for anemia and metabolic bone disease, but was not associated with lipid monitoring, differences in mean blood pressure (133/69 mmHg vs. 131/70 mmHg, p > 0.50) or blood pressure control. A subgroup analysis of Stage 4 CKD patients did not show a significant association between co-management and ACE/ARB prescription (80 % vs. 73 %, p = 0.26).

Conclusion

For stage 3 and 4 CKD patients, nephrology co-management was associated with increased stage-appropriate monitoring and ACE/ARB prescribing, but not improved blood pressure control.

【 授权许可】

   
2015 Samal et al.

【 参考文献 】

• [1]Mandell BF. The generalist, the specialist, and the patient with chronic kidney disease. Cleve Clin J Med. 2014; 81(5):273-4.
• [2]KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1-150.
• [3]Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L et al.. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010; 14(21):1-184.
• [4]Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011; 124(11):1073.
• [5]K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266.
• [6]Wright A, Pang J, Feblowitz JC, Maloney FL, Wilcox AR, McLoughlin KS et al.. Improving completeness of electronic problem lists through clinical decision support: a randomized, controlled trial. J Am Med Inform Assoc. 2012; 19(4):555-61.
• [7]K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5 Suppl 1):S1-290.
• [8]James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al.. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014; 311(5):507-20.
• [9]KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012; 2:337.
• [10]Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M et al.. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62(2):201-13.
• [11]Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ et al.. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2010; 55(5):773-99.
• [12]KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl (2011). 2012; 2(4):279-335.
• [13]KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009; 113:S1-130.
• [14]Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A et al.. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013; 62(5):849-59.
• [15]Ricardo AC, Roy JA, Tao K, Alper A, Chen J, Drawz PE, et al. Influence of nephrologist care on management and outcomes in adults with chronic kidney disease. J Gen Intern Med. 2015 Jul 3. [Epub ahead of print].
• [16]Samal L, Linder JA, Bates DW, Wright A. Electronic problem list documentation of chronic kidney disease and quality of care. BMC Nephrol. 2014; 15:70. BioMed Central Full Text
• [17]Parchman ML, Pugh JA, Romero RL, Bowers KW. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med. 2007; 5(3):196-201.
• [18]Ostbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005; 3(3):209-14.
• [19]Thilly N, Boini S, Kessler M, Briancon S, Frimat L. Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study. J Eval Clin Pract. 2009; 15(1):121-8.
• [20]Philipneri MD, Rocca Rey LA, Schnitzler MA, Abbott KC, Brennan DC, Takemoto SK et al.. Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. Clin Exp Nephrol. 2008; 12(1):41-52.
• [21]Litvin CB, Nietert PJ, Wessell AM, Jenkins RG, Ornstein SM. Recognition and management of CKD in primary care. Am J Kidney Dis. 2011; 57(4):646-7.
• [22]Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. J Gen Intern Med. 2011; 26(4):386-92.
• [23]Abdel-Kader K, Fischer GS, Johnston JR, Gu C, Moore CG, Unruh ML. Characterizing pre-dialysis care in the era of eGFR reporting: a cohort study. BMC Nephrol. 2011; 12:12. BioMed Central Full Text
• [24]Abdel-Kader K, Fischer GS, Li J, Moore CG, Hess R, Unruh ML. Automated clinical reminders for primary care providers in the care of CKD: a small cluster-randomized controlled trial. Am J Kidney Dis. 2011; 58(6):894-902.
• [25]Maclean CD, Gagnon M, Callas P, Littenberg B. The Vermont diabetes information system: a cluster randomized trial of a population based decision support system. J Gen Intern Med. 2009; 24(12):1303-10.
• [26]Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013; 310(7):699-705.
• [27]Mendu ML, Schneider LI, Aizer AA, Singh K, Leaf DE, Lee TH et al.. Implementation of a CKD checklist for primary care providers. Clin J Am Soc Nephrol. 2014; 9(9):1526-35.
• [28]Samal L, Linder JA, Lipsitz SR, Hicks LS. Electronic health records, clinical decision support, and blood pressure control. Am J Manag Care. 2011; 17(9):626-32.
• [29]Feblowitz JC, Wright A, Singh H, Samal L, Sittig DF. Summarization of clinical information: a conceptual model. J Biomed Inform. 2011; 44(4):688-99.
• [30]Samal L, Wright A, Wong BT, Linder JA, Bates DW. Leveraging electronic health records to support chronic disease management: the need for temporal data views. Inform Prim Care. 2011; 19(2):65-74.
• [31]Grant RW, Pandiscio JC, Pajolek H, Woulfe A, Pelletier A, Kvedar J et al.. Implementation of a web-based tool for patient medication self-management: the medication self-titration evaluation programme (med-STEP) for blood pressure control. Inform Prim Care. 2012; 20(1):57-67.
• [32]Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; 2:CD000011.
• [33]Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS et al.. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002; 137(6):479-86.
• [34]de Jager DJ, Voormolen N, Krediet RT, Dekker FW, Boeschoten EW, Grootendorst DC et al.. Association between time of referral and survival in the first year of dialysis in diabetics and the elderly. Nephrol Dial Transplant. 2011; 26(2):652-8.
• [35]Kim do H, Kim M, Kim H, Kim YL, Kang SW, Yang CW et al.. Early referral to a nephrologist improved patient survival: prospective cohort study for end-stage renal disease in Korea. PLoS One. 2013; 8(1):e55323.
• [36]Khan SS, Xue JL, Kazmi WH, Gilbertson DT, Obrador GT, Pereira BJ et al.. Does predialysis nephrology care influence patient survival after initiation of dialysis? Kidney Int. 2005; 67(3):1038-46.
• [37]Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F et al.. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant. 2001; 16(12):2357-64.
• [38]Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS et al.. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012; 59(4):504-12.
• [39]O’Hare AM, Batten A, Burrows NR, Pavkov ME, Taylor L, Gupta I et al.. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis. 2012; 59(4):513-22.
• [40]Lee BJ, Forbes K. The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease. BMJ. 2009; 339:b2395.
• [41]Lee B, Turley M, Meng D, Zhou Y, Garrido T, Lau A et al.. Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis. BMC Health Serv Res. 2012; 12:252. BioMed Central Full Text
• [42]Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D et al.. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305(15):1553-9.